41.09
0.37 (0.91%)
0.37 (0.91%)
Upgrade to Real-Time
Afterhours (Closed)
Low
10.83
High
56.74
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
Level 1 Starter
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| TG Therapeutics Inc | TGTX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| 0.37 | 0.91% | 41.09 | 18:26:05 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 41.02 | 40.15 | 42.1299 | 41.09 | 40.72 |
| Bid Price | Ask Price | Spread | News | |
|---|---|---|---|---|
| 41.10 | 41.98 | 0.88 | - | - |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 11,985 | 1,187,692 | $ 41.16 | $ 48,885,255 | 2,770,167 | 10.83 - 56.74 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:54:48 | 1 | $ 41.22 | USD |
TG Therapeutics Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 5.66B | 137.81M | 110.44M | $ 152.00k | $ - | -1.95 | -23.60 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
TG Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical TGTX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 45.15 | 49.3879 | 38.715 | 42.94 | 2,321,445 | -4.06 | -8.99% |
| 1 Month | 44.35 | 50.00 | 38.715 | 45.05 | 1,519,676 | -3.26 | -7.35% |
| 3 Months | 46.81 | 56.50 | 38.445 | 46.73 | 1,486,445 | -5.72 | -12.22% |
| 6 Months | 27.27 | 56.74 | 24.93 | 43.81 | 1,732,299 | 13.82 | 50.68% |
| 1 Year | 12.56 | 56.74 | 10.83 | 31.65 | 1,855,991 | 28.53 | 227.15% |
| 3 Years | 14.35 | 56.74 | 3.32 | 17.31 | 1,655,615 | 26.74 | 186.34% |
| 5 Years | 10.20 | 56.74 | 3.32 | 15.21 | 1,440,498 | 30.89 | 302.84% |
TG Therapeutics Description
| TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a unique epitope on the CD20 antigen found on mature B-lymphocytes. It is also developing TGR-1202 (umbralisib), an orally available PI3K delta inhibitor. |
